RG 001 - RinuaGene Biotechnology
Alternative Names: RG-001Latest Information Update: 28 Mar 2025
At a glance
- Originator RinuaGene Biotechnology
- Class COVID-19 vaccines; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
- 28 Mar 2025 QC feedbacks incorporated
- 28 Feb 2025 Preclinical trials in COVID-2019 infections (Prevention) in China (Parenteral), prior to February 2025 (RinuaGene Biotechnology pipeline, February 2025)
- 21 Apr 2023 RinuaGene Biotechnology has patents pending for "Mrna vaccine based on novel coronavirus" Worldwide